[
  {
    "symbol": "INSM",
    "price": 20.15,
    "beta": 1.526408,
    "volAvg": 1043622,
    "mktCap": 2749124789,
    "lastDiv": 0,
    "range": "16.04-28.94",
    "changes": 0.18,
    "companyName": "Insmed Incorporated",
    "currency": "USD",
    "cik": "0001104506",
    "isin": "US4576693075",
    "cusip": "457669307",
    "exchange": "NASDAQ Global Select",
    "exchangeShortName": "NASDAQ",
    "industry": "Biotechnology",
    "website": "https://www.insmed.com",
    "description": "Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.",
    "ceo": "Mr. William H. Lewis J.D., M.B.A.",
    "sector": "Healthcare",
    "country": "US",
    "fullTimeEmployees": "736",
    "phone": "908 977 9900",
    "address": "700 US Highway 202/206",
    "city": "Bridgewater",
    "state": "NJ",
    "zip": "08807",
    "dcfDiff": 3.6335,
    "dcf": 25.3235,
    "image": "https://financialmodelingprep.com/image-stock/INSM.png",
    "ipoDate": "2000-06-01",
    "defaultImage": false,
    "isEtf": false,
    "isActivelyTrading": true,
    "isAdr": false,
    "isFund": false
  }
]